Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The Institute Of Medicinal Biotechnology Chinese Academy Of Medical Sciences has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are split between 2 distinct examiners and 2 distinct art units. This distribution shows that each of the company's active applications is being reviewed by a different individual in a different technical group. For practitioners, this means that the prosecution of one case is unlikely to directly impact the procedural standing of the other.
DEKARSKE, MADELINE MCGUIRE is the busiest examiner for the company, with 1 busiest examiner pending action. Since this 1 busiest examiner pending action represents only half of the total 2 pending office actions, the company must manage two separate relationships at the patent office. The presence of 2 distinct examiners indicates that the company is navigating different examination styles within the Biotechnology & Pharmaceuticals sector. This decentralized approach requires a flexible strategy for each application.
The 2 distinct art units involved suggest that the technical subject matter of the filings is diverse enough to require review by different specialized groups. Because there is no concentration of cases with a single official, there is no opportunity to leverage a single favorable ruling across the entire portfolio. Success for the 2 pending office actions will depend on the ability to address the specific requirements of each of the 2 distinct examiners independently.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706087 | GROUP OF IMB-C5 SERIES COMPOUNDS HAVING ANTI-CORONAVIRUS ACTIVITY AND APPLICATION THEREOF | DEKARSKE, MADELINE MCGUIRE | — |
| 18030107 | A GROUP OF PEPTIDE DERIVATIVE OMICSYNINS WITH ANTIVIRAL ACTIVITY AND USES THEREOF | REYNOLDS, FRED H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706087 | GROUP OF IMB-C5 SERIES COMPOUNDS HAVING ANTI-CORONAVIRUS ACTIVITY AND APPLICATION THEREOF | DEKARSKE, MADELINE MCGUIRE | — |
| 18030107 | A GROUP OF PEPTIDE DERIVATIVE OMICSYNINS WITH ANTIVIRAL ACTIVITY AND USES THEREOF | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706087 | GROUP OF IMB-C5 SERIES COMPOUNDS HAVING ANTI-CORONAVIRUS ACTIVITY AND APPLICATION THEREOF | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18030107 | A GROUP OF PEPTIDE DERIVATIVE OMICSYNINS WITH ANTIVIRAL ACTIVITY AND USES THEREOF | REYNOLDS, FRED H | 1658 | §101§102§103 | Final Rejection | — | Pending | Apr 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitute Of Medicinal Biotechnology Chinese Academy Of Medical Sciences has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Madeline Mcguire Dekarske has the most, with 1 of Institute Of Medicinal Biotechnology Chinese Academy Of Medical Sciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
